Pathway for the development of drugs to treat irritable bowel syndrome: From molecule identification through approval

Irritable Bowel Syndrome

Volumn , Issue , 2009, Pages 1-15

  Mangel, Allen W ^a   Fehnel, Sheri E ^a   Earnshaw, Stephanie R ^a   Mangel, Tobin P ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895252309     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions.Version 2.1. April 2005. 2008 Available from:http://www.fmcpnet org/data/resource/-Format~Version_2_1~Final_Final.pdf.
2. Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions Version 2.1 Explanation. 2008 May 18. Available from:http://www.amcp.org/amcp.-ark?p=0F6E1295.
3. Akehurst, RL; Brazier, JE; Mathers, N; O'Keefe, C; Kaltenthaler, E; et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.Pharmacoeconomics, 2002; 20,455-62.
4. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, MD:American Gastroenterological Association; 2001. 2008 May 15. Available from:http://www.gastro.org/user-assets/Documents/burden-report.pdf.
5. Andresen, V; Camilleri, M. Irritable bowel syndrome:recent and novel therapeutic approaches. Drugs, 2006, 66, 1073-1088.
6. Azpiroz, F; Bouin, M; Camilleri, M; Mayer, EA; Poitras, P; , Serra, J; et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil, 2007, 19, 62-88.
7. Bloom, MA; Barghout, V; Kahler, KH; Bentkover, J; Kurth, H; Gralnek, IM; et al. Budget impact of tegaserod on a managed care organization formulary. Am J Manag Care. 2005, 11, S27-34.
8. Burton, MB; Gebhart, GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacology and Exp Ther, 1998, 285, 707-715.
9. Camilleri, M. Treating irritable bowel syndrome:overview, perspective and future therapies. Br J Pharmacol, 2004, 141, 1237-1248.
10. Camilleri, M; Mangel, AW; Fehnel, SE; Drossman, DA; Mayer, EA; Talley, NJ. Primary endpoints for irritable bowel syndrome trials:a review of performance of endpoints. Clin Gastroenterol Hepat, 2007, 5, 534-540.
11. Camilleri, M; Mayer, EA; Drossman, DA; Heath, A; Dukes, GE; McSorley, D et al. Improvement in pain and bowel function in female patients with alosetron, a 5HT3 receptor antagonist. Aliment Pharmacol Ther, 1999, 13, 1149-1159.
12. Camilleri, M; Northcutt, AR; Kong, S; Dukes, GE; McSorley, D; Mangel, AW. Efficacy and safety of alosetron in women with irritable bowel syndrome:a randomized, placebocontrolled trial. Lancet, 2000, 355, 1035-1040.
13. Camilleri, M; Chet, WY; Mayer, EA:Northcutt, AR; Heath, A; Dukes, GE; McSorley, D et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med, 2001, 161, 1733-1740.
14. Cash, B; Sullivan, S; Barghout, V. Total costs of IBS:employer and managed care perspective. Am J Manag Care, 2005, 11(1 Suppl), S7-S16.
15. Chang, L. Brain responses to visceral and somatic stimuli in irritable bowel syndrome:a central nervous system disorder? Gastroenterol Clin N Am, 2005, 34, 271-279.
16. Drossman, DA. Review article:an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther, 1999, 13, 3-14.
17. Francis, CY; Morris, J; Whorwell PJ. The irritable bowel severity scoring system:a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther, 1997, 11, 395-402.
18. Gralnek IM. Health care utilization and economic issues in irritable bowel syndrome. Eur JSurg Suppl, 1998, 73-76.
19. Harding, JP; Hamm, LR; Ehsanullah, RB; Heath, AT; . Sorrells, SC; Haw J; Dukes, et al. Use of a novel electronic data collection system in multicenter trials of irritable bowel syndrome. Aliment Pharm Ther 1997, 11, 1073-1076.
20. Inadomi, JM; Fennerty, MB; Bjorkman, D. Systematic review:the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18, 671-682.
21. Irvine, EJ; Whitehead, WE; Chey, WD; Matsueda, K; Shaw, M; Talley, NJ; Veldhuyzen van Zanten, SJ. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology, 2006, 130, 1538-1551.
22. Johanson, JF; Drossman, DA; Panas, R; Wahle, A; Ueno, R. Clinical trial:phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther, 2008, 27, 685-696.
23. Kellow, J; Lee, OY; Chang, FY; Thongsawat, S; Mazlam, MZ; Yuen, H et al. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut, 2000 52, 671-676.
24. Lembo, AJ. The clinical and economic burden of irritable bowel syndrome. Practical Gastroenterol, September supplement, 2007, 3-9.
25. Leong, SA; Barghout, V; Birnbaum, HG; Thibeault, CE; Ben-Hamadi, R; Frech, F et al. The economic consequences of irritable bowel syndrome:a US employer perspective. Arch Intern Med, 2003, 28, 929-935.
26. Leventer, SM; Raudibaugh, K; Frissora, CL; Kassem, N; Keogh, JC; Phillips, J et al. Clinical trial:dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther, 2008, 27, 197-206.
27. Levy, RL; Von Korff, M; Whitehead, WE; Stang, P; Saunders, K; Jhingran, P; et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol, 2001, 96, 3122-3129.
28. Longstreth, GF; Thompson WG; Chey, WD; Houghton, LA; Mearin, F; Spiller; RC.Functional bowel disorders. Gastroenterol, 2006, 130, 1480-1491.
29. Longstreth, GF; Wilson, A; Knight, K; Wong, J; Chiou, C-F; Barghout, V, et al., Irritable bowel syndrome, health care use and costs:a U.S. manged care perspective. Am J Gastroenterol, 2003, 98, 600-607.
30. Malagelada, JR. Review article:clinical pharmacology models of irritable bowel syndrome. Aliment Pharmacol Ther, 1999, 13, 57-64.
31. Mangel, AW. Study design issues in irritable bowel syndrome. Aliment Pharmacol Ther, 2004, 19, 141-142.
32. Mangel, AW. Personal view:adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther, 2006, 23, 879-881.
33. Mangel, AW; Fehnel, SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther, 2005, 22, 1162-1163.
34. Mangel, AW; Bornstein, JD; Hamm, LR; Buda, J; Wang, J; Irish, W; et al. Aliment Pharm Ther, 2008, 28, 239-249.
35. Mangel, AW; Hahn, BA; Heath, AT; Northcutt, AR; Kong, S; Dukes, GE; et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res, 1998, 26, 76-81.
36. Mangel, AW; Northcutt, AR. Review article:the safety and efficacy of alosetron, a 5HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther, 1999, 13, 77-82.
37. Martin, BC; Ganguly, R; Pannicker, S; Frech, F; Barghout, V. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin, 2003, 19(8), 771-780.
38. Maxion-Bergemann, S; Thielecke, F; Abel, F; Bergemann, R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics, 2006, 24(1), 21-37
39. Mayer, EA. Irritable bowel syndrome. N Eng J Med, 2008, 358, 1692-1699.
40. Mayer, EA; Bradesi, S; Chang, L; Spiegel, BMR; Bueller, JA; Naliboff, BD. () Functional GI disorders:from animal models to drug development. Gut, 2008, 57, 384-404.
41. Muller-Lissner, SA; Fumagalli, I; Bardhan, KD; Pace, F; Pecher, E; Nault, B; et al. Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther, 2001, 15, 1655-1666.
42. Novick, L, Miner, P, Krause, R, Glebas, K, Bliesath, H, Ligozio, G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndromw with constipation. Aliment Pharmacol Ther, 2002, 16, 1877-1888.
43. Pappas, TN; Mangel, AW; Lawson, CL. Review article:evaluation of drugs in experimental gut distension models. Aliment Pharmacol Ther, 1999, 13(suppl 2), 54-56.
44. Patel, RP; Petitta, A; Fogel, R; Peterson, E; Zarowitz, BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol, 2002; 35(1):14-20.
45. Tennis, P; Andrews, E; Hickman, P; Miller, D; Hollis, K, Cook, S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up program. Aliment Pharmacol Ther, 2007, 25, 317-322.
46. US Department of Health and Human Services. Food and Drug Administration.CDER2002193, docket no. 2006D-0044, Guidance for Industry Patient-Reported Outcome Measures:Use in Medical Product Development to Support Labeling Claims Draft Guidance. 2006. 2008. Available from:http://www.fda.gov/cder/-guidance/5460dft.pdf.
47. Watson, ME; Lacey, L; Kong, S; Northcutt, AR; McSorley, D; Hahn, B; Mangel, AW. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastro, 2001, 96, 455-459.
48. Zacker, C; Chawla, AJ; Wang, S; Albers, LA. Absenteeism among employees with irritable bowel syndrome. Manag Care Interface, 2004, 17(5), 28-32.